Literature DB >> 21704010

MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy.

E Shen1, Xuehong Diao, Xiaoxia Wang, Ruizhen Chen, Bing Hu.   

Abstract

Cardiac hypertrophy is a key structural feature of diabetic cardiomyopathy in the late stage of diabetes. Recent studies show that microRNAs (miRNAs) are involved in the pathogenesis of cardiac hypertrophy in diabetic mice, but more novel miRNAs remain to be investigated. In this study, diabetic cardiomyopathy, characterized by hypertrophy, was induced in mice by streptozotocin injection. Using microarray analysis of myocardial tissue, we were able to identify changes in expression in 19 miRNA, of which 16 miRNAs were further validated by real-time PCR and a total of 3212 targets mRNA were predicted. Further analysis showed that 31 GO functions and 16 KEGG pathways were enriched in the diabetic heart. Of these, MAPK signaling pathway was prominent. In vivo and in vitro studies have confirmed that three major subgroups of MAPK including ERK1/2, JNK, and p38, are specifically upregulated in cardiomyocyte hypertrophy during hyperglycemia. To further explore the potential involvement of miRNAs in the regulation of glucose-induced cardiomyocyte hypertrophy, neonatal rat cardiomyocytes were exposed to high glucose and transfected with miR-373 mimic. Overexpression of miR-373 decreased the cell size, and also reduced the level of its target gene MEF2C, and miR-373 expression was regulated by p38. Our data highlight an important role of miRNAs in diabetic cardiomyopathy, and implicate the reliability of bioinformatics analysis in shedding light on the mechanisms underlying diabetic cardiomyopathy.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704010      PMCID: PMC3157194          DOI: 10.1016/j.ajpath.2011.04.034

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling.

Authors:  Pratima Malekar; Marco Hagenmueller; Adamma Anyanwu; Sebastian Buss; Marcus R Streit; Celine S Weiss; David Wolf; Johannes Riffel; Alexander Bauer; Hugo A Katus; Stefan E Hardt
Journal:  Hypertension       Date:  2010-02-22       Impact factor: 10.190

2.  Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy.

Authors:  Y Zou; Y Hiroi; H Uozumi; E Takimoto; H Toko; W Zhu; S Kudoh; M Mizukami; M Shimoyama; F Shibasaki; R Nagai; Y Yazaki; I Komuro
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

3.  Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload.

Authors:  G Esposito; S V Prasad; A Rapacciuolo; L Mao; W J Koch; H A Rockman
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

4.  MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium.

Authors:  S M Kolodziejczyk; L Wang; K Balazsi; Y DeRepentigny; R Kothary; L A Megeney
Journal:  Curr Biol       Date:  1999-10-21       Impact factor: 10.834

5.  Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes.

Authors:  T G Parker; S E Packer; M D Schneider
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

6.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

Review 7.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Zhi You Fang; Johannes B Prins; Thomas H Marwick
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

8.  Rac1 is required for cardiomyocyte apoptosis during hyperglycemia.

Authors:  E Shen; Yanwen Li; Ying Li; Limei Shan; Huaqing Zhu; Qingping Feng; J Malcolm O Arnold; Tianqing Peng
Journal:  Diabetes       Date:  2009-07-10       Impact factor: 9.461

9.  Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.

Authors:  Julie R McMullen; Megan C Sherwood; Oleg Tarnavski; Li Zhang; Adam L Dorfman; Tetsuo Shioi; Seigo Izumo
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

10.  Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy.

Authors:  Nobutake Shimojo; Subrina Jesmin; Sohel Zaedi; Takeshi Otsuki; Seiji Maeda; Naoto Yamaguchi; Kazutaka Aonuma; Yuichi Hattori; Takashi Miyauchi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-16       Impact factor: 4.733

View more
  36 in total

Review 1.  Proteinaceous cysteine protease inhibitors.

Authors:  G Dubin
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

Review 2.  Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention.

Authors:  Rui Guo; Sreejayan Nair
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-24       Impact factor: 5.187

3.  Defining miRNA targets: balancing simplicity with complexity.

Authors:  Jane E Freedman; Kahraman Tanriverdi
Journal:  Circulation       Date:  2013-04-26       Impact factor: 29.690

Review 4.  MicroRNAs and diabetic complications.

Authors:  Rama Natarajan; Sumanth Putta; Mitsuo Kato
Journal:  J Cardiovasc Transl Res       Date:  2012-05-03       Impact factor: 4.132

5.  Role of microRNAs in the pathogenesis of diabetic cardiomyopathy.

Authors:  Xinyu Liu; Shixue Liu
Journal:  Biomed Rep       Date:  2017-01-12

Review 6.  The Emerging Role of Thioredoxin-Interacting Protein in Myocardial Ischemia/Reperfusion Injury.

Authors:  Bing F Wang; Jun Yoshioka
Journal:  J Cardiovasc Pharmacol Ther       Date:  2016-11-02       Impact factor: 2.457

7.  MicroRNA-200c modulates DUSP-1 expression in diabetes-induced cardiac hypertrophy.

Authors:  Gurinder Bir Singh; Satish K Raut; Sanskriti Khanna; Akhilesh Kumar; Saurabh Sharma; Rishikesh Prasad; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2016-09-30       Impact factor: 3.396

Review 8.  MicroRNAs: potential mediators and biomarkers of diabetic complications.

Authors:  Mitsuo Kato; Nancy E Castro; Rama Natarajan
Journal:  Free Radic Biol Med       Date:  2013-06-12       Impact factor: 7.376

9.  Identifying disrupted pathways by tracking altered modules in type 2 DM-related heart failure.

Authors:  H Liu; X Han; Y Li
Journal:  Herz       Date:  2016-06-30       Impact factor: 1.443

Review 10.  Diabetic cardiomyopathy and metabolic remodeling of the heart.

Authors:  Pavan K Battiprolu; Camila Lopez-Crisosto; Zhao V Wang; Andriy Nemchenko; Sergio Lavandero; Joseph A Hill
Journal:  Life Sci       Date:  2012-10-30       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.